City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...